This randomized, single dose, three-way crossover study will evaluate the bioequivalence of
two formulations of colchicine, the test product (colchicine 0.6mg Mutual) and a marketed
combination product (colchicine 0.5 mg with probenecid 500 mg), administered under fasting
conditions. It will also determine the bioavailability following a standard high-fat meal and
evaluate the safety and tolerability of the test product.